首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
【24h】

Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.

机译:通过扩散和灌注MRI监测静脉内重组组织纤溶酶原激活剂溶栓治疗的急性缺血性中风。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Intravenous recombinant tissue plasminogen activator (rtPA) administration is an effective therapy for ischemic stroke when initiated within 3 hours and possibly up to 6 hours after symptom onset. To improve patient selection, a fast diagnostic tool that allows reliable diagnosis of hemorrhage and ischemia, vessel status, and tissue at risk at an early stage may be useful. We studied the feasibility of stroke MRI for the initial evaluation and follow-up monitoring of patients undergoing intravenous thrombolysis. METHODS: Stroke MRI (diffusion- and perfusion-weighted imaging [DWI and PWI, respectively], magnetic resonance angiography, and T2-weighted imaging) was performed before, during, or after thrombolysis and on days 2 and 5. We assessed clinical scores (National Institutes of Health Stroke Scale [NIHSS], Scandinavian Stroke Scale [SSS], Barthel Index, and Rankin scale) at days 1, 2, 5, 30, and 90. Furthermore, we performed volumetric analysis of infarct volumes on days 1, 2, and 5 as shown in PWI, DWI, and T2-weighted imaging. RESULTS: Twenty-four patients received rtPA within a mean time interval after symptom onset of 3.27 hours and stroke MRI of 3.43 hours. Vessel occlusion was present in 20 of 24 patients; 11 vessels recanalized (group 1), and 9 did not (group 2). The baseline PWI lesion volume was significantly larger (P=0.008) than outcome lesion size in group 1, whereas baseline DWI lesion volume was significantly smaller (P=0.008) than final infarct size in group 2. Intergroup outcome differed significantly for all scores at days 30 and 90 (all P<0.01). Intragroup differences were significant in group 1 for change in SSS and NIHSS between day 1 and day 30 (P=0.003) and for SSS only between day 1 and day 90 (P=0.004). CONCLUSIONS: Stroke MRI provides comprehensive prognostically relevant information regarding the brain in hyperacute stroke. Stroke MRI may be used as a single imaging tool in acute stroke to identify and monitor candidates for thrombolysis. It is proposed that stroke MRI is safe, reliable, and cost effective; however, our data do not prove this assumption. Early recanalization achieved by thrombolysis can save tissue at risk if present and may result in significantly smaller infarcts and a significantly better outcome.
机译:背景与目的:静脉内重组组织纤溶酶原激活剂(rtPA)给药是在症状发作后3小时内(可能长达6小时内)开始治疗缺血性中风的有效方法。为了改善患者选择,可以使用快速诊断工具来可靠地诊断出血和局部缺血,血管状态以及早期有风险的组织。我们研究了中风MRI在进行静脉溶栓治疗的患者的初始评估和随访监测中的可行性。方法:在溶栓之前,期间或之后以及第2和5天进行中风MRI(分别为弥散和灌注加权成像[分别为DWI和PWI],磁共振血管造影和T2加权成像)。我们评估了临床评分(美国国立卫生研究院卒中量表[NIHSS],斯堪的纳维亚卒中量表[SSS],Barthel指数和Rankin量表)在第1、2、5、30和90天进行。此外,我们在第1天进行了梗死体积的体积分析。 ,2和5,如PWI,DWI和T2加权成像所示。结果:24名患者在症状发作3.27小时和中风MRI后3.43小时的平均时间间隔内接受rtPA。 24名患者中有20名存在血管闭塞。再通11艘血管(第1组),再通9艘(第2组)。在第1组中,基线PWI病变体积显着大于(P = 0.008),而在第2组中,基线DWI病变体积显着小于(P = 0.008)。在所有评分下,组间结局均存在显着差异第30天和第90天(所有P <0.01)。第1组的第1天至第30天之间的SSS和NIHSS变化组内差异显着(P = 0.003),而第1天至第90天之间的SSS仅变化(P = 0.004)。结论:卒中MRI可提供有关超急性卒中大脑的全面预后相关信息。卒中MRI可用作急性卒中的单个成像工具,以识别和监测溶栓的候选人。建议卒中MRI安全,可靠且具有成本效益。但是,我们的数据不能证明这一假设。通过溶栓作用实现的早期再通可以挽救组织(如果存在)的风险,并可能导致梗死面积明显缩小和结局明显改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号